Systemic therapy of psoriasis: Methotrexate

Bratislava Medical Journal

Volumn 112, Issue 7, 2011, Pages 390-394

  Kozub, P ^a   Simaljakova, M ^a  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Folic acid; Methotrexate; Psoriasis

Indexed keywords

ANTIINFLAMMATORY AGENT; FOLIC ACID ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ARTICLE; HUMAN; PSORIASIS; PSORIATIC ARTHRITIS;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; FOLIC ACID ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PSORIASIS;

EID: 79960507515     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Flytstrom I et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-121.
2. Saurat JH et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. place bo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
3. Hughes LB et al. Recent advances in rheumatoid arthritis therapy and management: recent advances in predictors of efficacy and toxicity. www.medscape.com
4. Braun J et al. Comparison of the clinical efficacy and safety of sub cutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-months, multicenter, rando mized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73-81.
5. Methotrexat-Lachema, siihrn charakteristickych vlastnosti lieku (SPC), www.nobelplus.sk
6. Boffa M. Methotrexate for psoriasis - an update. Spring symposium EADV Bucharest 2009.
7. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety an efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009; 160: 622-628.
8. Dervieux T et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase and thymidilate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2766-2774.
9. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75-84.
10. Warren RB et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160: 438-441.
11. Warren RB et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Inv Dermatol 2008; 128: 1925-1929.
12. Campalani E et al. Polymorphisms in folate, pyrimidine and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Inv Dermatol 2007; 127: 1860-1867.
13. Hroch M et al. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. JEADV 2007; 22: 19-24.
14. MZ SR. Zoznam liekov a lieciv pine uhradzanych alebo ciastocne uhradzanych na zaklade verejneho zdravotneho poistenia: http://www.health.gov.sk